Our aim is to make ultra-rapid medical diagnosis available everywhere, helping to reduce the number of casualties from a delayed medical response or from potentially fatal misdiagnosis.
We believe our cutting-edge technology will lead the future of medical analysis, by providing solutions to a vast amount of current medical challenges.
The company was founded in 2010 as a spinoff from the Swiss Federal Institute of Technology of Lausanne (EPFL), by Dr. Nicolas Durand and Dr. Iwan Märki. In 2015 the first range of respiratory allergen diagnostics was commercialised. Abionic is today an active sponsor of the Global Sepsis Alliance, aiming to raise awareness of Sepsis. Abionic has recently obtained U.S. Food and Drug Administration registration for rapid diagnostic tests.
Our dynamic team has been recognised as one of the most efficient in Switzerland. In less than 8 years, we have demonstrated the ability to bring the company to a stage of full expansion. Currently, our team is composed of 44+ highly skilled employees including 8 PhDs. The team at Abionic is committed to changing the world of In Vitro Diagnostics (IVD) and bringing accessible healthcare solutions to everyone.
Abionic’s quality management system is certified for meeting the requirements of ISO 13485:2016 standards for R&D and commercialisation of IVD products. Abionic has been operating with high-quality standards and complying with international regulations, while ensuring that production meets the Swiss healthcare standards.
ISO 13485:2016 certification obtained
Sepsis Test (PSP) (CE) marking obtained & first clinical demonstration
IVD CAPSULE, Ferritin
Swiss Economic Forum Label
Proud Ambassador of Health Valley Switzerland
IVD CAPSULE Aeroallergen (CE) certification obtained & first products sold
First distribution partnership in Switzerland achieved
Fund-raising of 8.2 million Swiss francs in series B
Swiss Excellence Product Award
abioSCOPE (CE) certification obtained
ISO 13485:2003 certification obtained
Abionic was founded